Anthony Macdonald: Investors certainly aren’t going anywhere at Cochlear, which had a stonking year, and has issued strong guidance for 2024.
Chief executive Dig Howitt said revenue in 2023 was better than expected thanks to market growth, market share gains, improved clinical capacity and more COVID-catch-up surgeries than expected.
What we learnt from Temple & Webster, Cochlear and Pro Medicus’ results comes via ChinaTechNews.com.